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Japanese patients
Naoki Terada1,2, Toshiyuki Kamoto1, Hiromasa Tsukino1, Shoichiro Mukai1, Shusuke Akamatsu2, Takahiro Inoue2,
Osamu Ogawa2, Shintaro Narita3, Tomonori Habuchi3, Shinichi Yamashita4, Koji Mitsuzuka4, Yoichi Arai4,
Shuya Kandori5, Takahiro Kojima5, Hiroyuki Nishiyama5, Yoshiaki Kawamura6, Yuki Shimizu6, Toshiro Terachi6,
Motohiko Sugi7, Hidefumi Kinoshita7, Tadashi Matsuda7, Yusuke Yamada8, Shingo Yamamoto8, Hiromi Hirama9,
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Abstract
Background: We analyzed the efficacy and toxicity of cabazitaxel (CBZ) at high and low initial doses in Japanese
patients with docetaxel-resistant castration-resistant prostate cancer (CRPC).
Methods: We retrospectively evaluated 118 patients who received CBZ for docetaxel-resistant CRPC in 10 university
hospitals in Japan between 2014 and 2016. The rate of decrease of prostate-specific antigen (PSA), adverse events,
progression-free survival (PFS), and overall survival (OS) were compared between patients receiving initially high
(≥22.5 mg/m2, n = 36) and low (≤20 mg/m2, n = 80) CBZ doses. Factors associated with survival and grade 4
neutropenia were evaluated.
Results: PSA values decreased by > 50% in 22 patients (19%), with a higher frequency in the high-dose group than
in the low-dose group (29 and 14%, P = 0.073). The median PFS time for the all-patient, high- and low-dose groups
was 2.8 months (95% confidence interval [CI] 1.9–4.4), 2.1 months (1.2–5.5), and 3.0 months (2.0–4.4), respectively (P
= 0.904). The median OS times were 16.3 months (95% CI 9.7–30.9), 30.9 months (11.8–47.4), and 10.2 months (8.6–
20), respectively (P = 0.020). In multivariate analyses, PFS was significantly associated with existing bone metastasis
at diagnosis (P = 0.005) and OS with PSA > 100 ng/ml (P = 0.007), hemoglobin < 12 g/dl (P = 0.030), and low initial
CBZ dose (P = 0.030). Grade 4 neutropenia occurred in 53 patients (45%) and was associated with a low CBZ dose
(hazard ratio 0.21, 95% CI 0.08–0.59, P = 0.002).
Conclusions: CBZ at a higher initial dose may have similar response rate and response duration, but longer survival
duration after treatment with higher toxicity than a lower initial dose for docetaxel-resistant CRPC in Japanese patients.
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Background
Prostate cancer is the second leading cause of
cancer-related death in men in the USA [1] and its inci-
dence in Japan is increasing rapidly [2]. Between 10 and
15% of patients present with advanced disease and receive
hormone therapy as their initial treatment. However, most
cases acquire therapy resistance within 2 years and then
progress to castration-resistant prostate cancer (CRPC)
[3]. In recent years, an increasing number of effective sys-
temic therapies for metastatic CRPC have become avail-
able, including novel hormone treatments and taxane
chemotherapies. Docetaxel was shown in 2004 to prolong
the survival of patients with CRPC and was previously the
only approved treatment [4]. Cabazitaxel (CBZ) is a taxane
drug with activity against docetaxel-resistant cancers [5].
Overall survival (OS) of men with metastatic CRPC who
had progressed after docetaxel-based chemotherapy was
better after treatment with CBZ plus prednisone com-
pared with mitoxantrone plus prednisone [6]. Based pri-
marily on the results of that study [6], 25mg/m2 CBZ in
combination with prednisone was approved for the treat-
ment of CRPC patients previously treated with docetaxel.
Subsequent reports suggested that 20mg/m2 CBZ might
decrease myelotoxicity without altering efficacy [7]. How-
ever, the association between CBZ dose, efficacy, and tox-
icity has not been evaluated in Japanese patients with
CRPC. The aim of this retrospective multi-institutional
study was to evaluate the efficacy and toxicity of CBZ in




This was a retrospective study of 118 patients who re-
ceived CBZ for docetaxel-resistant CRPC at 10 university
and satellite hospitals in Japan between 2014 and 2016.
The study was approved by the institutional review board
of each university. All patients had pathologically proven
adenocarcinoma of the prostate that was progressing ac-
cording to prostate-specific antigen (PSA) concentrations
or radiographic criteria, despite androgen blockade ther-
apy. The data were retrospectively obtained from medical
records. CRPC was defined as either an increase in PSA
level of > 25% relative to the nadir PSA value or radio-
logical progression after initial hormonal therapy. All
CRPC patients had received docetaxel before CBZ treat-
ment. The criteria for decision making about CBZ doses
was different between institutions and not determined.
The rate of PSA decrease, incidence of adverse events,
and duration of progression-free survival (PFS) and OS
were compared between patients who received a first
course of CBZ treatment of 25 or 22.5mg/m2 (the
high-dose group, n = 37) or 20 or 15mg/m2 (the low-dose
group, n = 81). The relative dose intensity (RDI) of CBZ
was calculated as the ratio of delivered dose intensity (mg/
m2/week) to the planned dose intensity (25mg/m2, every
3 weeks) in the first three cycles of CBZ treatment. PFS
was defined as the time from initiation of CBZ to an in-
crease in PSA value > 25% relative to the nadir PSA value,
radiological progression, or death after CBZ treatment.
OS was defined as the time from initiation of CBZ treat-
ment to death from any cause. The type and incidence of
adverse events were also evaluated based on the laboratory
data and medical records.
Statistical analysis
The data are presented as medians and ranges. PFS and OS
times were estimated using the Kaplan–Meier method and
compared using the log-rank test. Associations between
clinicopathological variables and prognosis were assessed
using univariate and multivariate Cox’s proportional haz-
ards regression models. The median values were used as
cut-off values of the subgroups. Associations with adverse
events were examined using multivariate logistic regression
analysis. All statistical analyses were performed with EZR
(Saitama Medical Center, Jichi Medical University, Saitama
Japan), which is a graphical user interface for R (R Founda-
tion for Statistical Computing, Vienna, Austria). P values of
< 0.05 were considered statistically significant.
Results
In total, 118 patients were treated with CBZ. Of these, 37
(31%) were in the high-dose group (30 received 25mg/m2,
7 received 22.5mg/m2 initially) and 81 (69%) were in the
low-dose group (75 received 20mg/m2, 6 received 15mg/
m2 initially). The clinicopathological characteristics for the
patients in the high- and low-dose groups are shown in
Table 1. Significantly more patients in the low-dose group
than in the high-dose group had a performance status (PS)
≥1 (60 and 35%, respectively, P = 0.017), but there were no
significant differences in other parameters. Patients were
administered one dose of CBZ every 3 to 4 weeks (28 in 3
weeks and 90 in 4 weeks) and the median number of treat-
ment cycles was 4 (range 1–33). During treatment, the
CBZ dosage was decreased due to adverse events in 13 pa-
tients (35%) in the high-dose group and 6 patients (7%) in
the low-dose group. Dosage was increased in 4 patients
(5%) in the low-dose group and none in the high-dose
group. RDI was calculated in 29 patients (78%) in the
high-dose group and 56 patients (69%) in the low-dose
group who received three or more cycles of CBZ treat-
ment. The median RDI was 75% (60–100%) in the
high-dose group and it was 60% (30–80%) in the low-dose
group (P < 0.001) (Table 1). Prior treatments were surgery
or radiation as local treatments (38/118, 32%), and abira-
terone or enzalutamide (93/118, 79%). All patients had pre-
viously been treated with docetaxel (median 7 treatment
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cycles, range 1–61). In 97 patients (82%), pegfilgrastim was
administered after the CBZ treatment.
The median follow-up duration was 8.2months (range
1–50). PSA values decreased by > 50% in 22 patients
(19%), with a higher frequency in the high-dose group
(11/37, 29%) than in the low-dose group (11/81, 14%).
However, this difference was not statistically significant (P
= 0.073; Fig. 1). The median PFS time after CBZ treatment
for all patients was 2.8 months (95% confidence interval
[CI] 1.9–4.4; Fig. 2a) and there was no significant differ-
ence in PFS between the high- (median 2.1 months, 95%
CI 1.2–5.5) and low-dose (median 3.0 months, 95% CI
2.0–4.4) groups (P = 0.904 by log-rank test; Fig. 2b). Uni-
variate analysis of the association between PFS and age >
70 years, PS ≥1, total Gleason score ≥ 9, PSA > 100 ng/ml,
hemoglobin < 12 g/dl, lactate dehydrogenase > 300 U/L,
alkaline phosphatase > 350 U/L, presence of bone metas-
tasis at diagnosis, time to CRPC < 1 year, previous doce-
taxel cycle < 10, previous abiraterone or enzalutamide
treatment, initial low CBZ dose and RDI 60% or lower re-
vealed that only the presence of bone metastasis at
diagnosis was significantly associated with PFS (hazard ra-
tio [HR] 1.55, 95% CI 1.03–2.34, P = 0.037), and this
remained the only significantly associated factor after
multivariate analysis including low initial CBZ dose (HR
1.03, 95% CI 1.03–2.37, P = 0.037; Table 2).
The median OS time after CBZ treatment was 16.3
months (95% CI 9.7–30.9; Fig. 3a). OS was significant
longer in the high-dose group than the low-dose group
(median 30.9 months, 95% CI 11.8–47.4 vs 10.2 months,
95% CI 8.6–20; P = 0.020 by log-rank test; Fig. 3b). Uni-
variate Cox’s proportional hazard analysis identified sig-
nificant association between OS and PS ≥1 (HR 3.14,
95% CI 1.63–6.04, P = 0.001), PSA > 100 ng/ml (HR 2.55,
95% CI 1.41–4.58, P = 0.002), hemoglobin < 12 g/dl (HR
1.95, 95% CI 1.03–3.72, P = 0.042), lactate dehydrogenase
> 300 U/L (HR 2.03, 95% CI 1.10–3.74, P = 0.023), alka-
line phosphatase > 350 U/L (HR 1.98, 95% CI 1.07–3.67,
P = 0.03), initial low CBZ dose (HR 2.22, 95% CI 1.11–
4.43, P = 0.023), and RDI 60% or lower (HR 2.76, 95% CI
1.24–6.17, P = 0.013). In multivariate analyses including
these parameters, only the association with PSA > 100
Table 1 Patients background in high and low initial CBZ dose groups
Factors Total (n = 118) High (n = 37) Low (n = 81) P (High vs Low)
Median age at diagnosis (y) 65 (47–81) 65 (47–76) 66 (49–81) 0.087
Median PSA at diagnosis (ng/mL) 61.0 (5.0–21,114) 61.2 (3.2–21,114) 61.0 (5.0–9430) 0.840
GS at diagnosis≥9 70 (61%) 25 (68%) 45 (55%) 0.290
Metastatic status at diagnosis No: 34 (29%) No: 11 (30%) No: 23 (28%) 0.528
LN:15 (13%) LN:5 (14%) LN:10 (12%)
Bone< 6:37 (31%) Bone< 6:8 (22%) Bone< 6:29 (36%)
Bone> 5:24 (20%) Bone> 5:10 (27%) Bone> 5:14 (17%)
Visceral:8 (7%) Visceral:3 (8%) Visceral:5 (6%)
Median age at CBZ start (y) 70 (48–88) 70 (48–79) 72 (50–88) 0.182
Median PSA at CBZ start (ng/ml) 75.2 (0.07–9586) 52.3 (3.44–1610) 78.0 (0.07–9586) 0.550
PS at CBZ start≥1 62 (53%) 13 (35%) 49 (60%) 0.017*
Median RDI of CBZ 60% (30–100%) 75% (60–100%) 60% (30–80%) < 0.001*
PS performance status, RDI relative dose intensity *P < 0.05
Fig. 1 Waterfall plot of the PSA changes treated by cabazitaxel. The > 50% PSA decrease rate was 19% (22/118) in total. The PSA decrease rates in
> 20 mg/m2 (red) and≤ 20 mg/m2 (blue) were 29% (11/37) and 14% (11/81), respectively (P = 0.073)
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ng/ml (HR 2.35, 95% CI 1.07–5.18, P = 0.034) remained
significant. Then, using stepwise regression multivariate
analyses, PSA > 100 ng/ml (HR 2.84, 95% CI 1.33–6.03,
P = 0.007), hemoglobin < 12 g/dl (HR 2.50, 95% CI 1.09–
5.73, P = 0.030) and low initial CBZ dose (HR 2.81, 95%
CI 1.11–7.13, P = 0.030) were significantly correlated
with OS (Table 3).
The number of patients with CBZ-related adverse events
is shown in Table 4. Thirteen patients (11%) terminated
treatment due to adverse events. There were significant dif-
ferences between the high and low CBZ dose groups in the
incidence of grade 4 neutropenia (65 and 36%, respectively,
P < 0.001) and grade 3 thrombocytopenia (16 and 4%, re-
spectively, P = 0.026; Table 4). Univariate and multivariate
logistic regression analyses of the association between grade
4 neutropenia and age, PS, docetaxel cycle, pegfilgrastim
use, and low CBZ dose revealed that only low CBZ dose
was significantly associated (univariate HR 0.21, 95% CI
0.08–0.52, P = < 0.001, multivariate HR 0.21, 95% CI 0.08–
0.59, P = 0.002; Table 5).
Discussion
Based on the results of the phase III TROPIC trial, CBZ at
25mg/m2 in combination with prednisone was approved
A B
Fig. 2 Progression-free survival (PFS) after cabazitaxel treatment. a PFS in the all-patient cohort (median survival 2.8 months, 95% CI 1.9–4.4). b
PFS in the patients with the high initial CBZ dose (high-dose) group (median survival 2.1 months, 95% CI 1.2–5.5) and with the low initial CBZ
dose (low-dose) group (median survival 3.0 months, 95% CI 2.0–4.4). P = 0.904 by log-rank test
Table 2 Cox proportional hazard analyzes for PFS after CBZ treatment
Univariate Multivariate
Odds ratio (95% CI) P Odds ratio (95% CI) P
Age (y) > 70 0.90 (0.60–1.35) 0.617
PS ≥ 1 1.04 (0.69–1.56) 0.864
GS≥ 9 1.00 (0.65–1.53) 0.982
PSA (ng/ml) > 100 0.93 (0.62–1.41) 0.743
Hb (g/dl) < 12 1.245 (0.828–1.871) 0.292
LDH (U/L) > 300 1.28 (0.81–2.02) 0.298
ALP (U/L) > 350 0.93 (0.62–1.40) 0.739
Bone meta at diagnosis 1.55 (1.03–2.34) 0.037* 1.03 (1.03–2.37) 0.037*
Time to CRPC (y) < 1 1.19 (0.79–1.79) 0.4
DTX cycle< 10 1.40 (0.92–2.13) 0.121
ABI or ENZA 0.73 (0.45–1.17) 0.184
Low initial CBZ dose 1.03 (0.67–1.58) 0.905 0.95 (0.62–1.47) 0.832
RDI 60% or lower 0.86 (0.54–1.39) 0.545
PS performance status, DTX docetaxel, ABI abiraterone, ENZ enzalutamide
RDI relative dose intensity, *P < 0.05
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in 2010 for the treatment of patients with CRPC previ-
ously treated with docetaxel. However, severe
hematological toxicity was reported, and the possibility
was raised that lower doses might be required to reduce
myelotoxicity. This was tested in the phase III PROSE-
LICA study, which evaluated the noninferiority and safety
of 20mg/m2 CBZ compared with 25mg/m2. PSA re-
sponse rates of > 50% were significantly higher in the 25
mg/m2 group (42.9%) than the 20mg/m2 group (29.5%, P
= 0.001). However, there was no significant difference in
either the median PFS time (2.9 and 3.5months in the 20
mg/m2 and 25mg/m2 groups, HR 1.099, 95% CI 0.974–
1.240) or median OS time (13.4 and 14.5months in the
20mg/m2 and 25mg/m2 groups, HR 1.024, 95% CI
0.989–1.184) between the treatment groups. We found a
similar PFS in the two treatment groups even though the
PSA decrease rate tended to be lower in the low initial
CBZ dose group. In contrast, the high-dose group had a
significantly longer OS than did the low-dose group in
univariate and multivariate Cox proportional hazard ana-
lyses. The RDI was significantly higher in the high-dose
group. Based on these results, the initial high-dose CBZ
A B
Fig. 3 Overall survival (OS) after cabazitaxel treatment. a OS in the all-patient cohort (median survival 16.3 months, 95% CI 19.7–30.9). b OS in the
patients with the high initial CBZ dose (high-dose) group (median survival 30.9 months, 95% CI 11.8–47.4) and with the low initial CBZ dose (low-
dose) group (median survival 10.2 months, 95% CI 8.6–20). P = 0.020 by log-rank test
Table 3 Cox proportional hazard analyzes for OS after CBZ treatment
Univariate Multivariate Multivariate (Stepwise)
Odds ratio (95% CI) P Odds ratio (95% CI) P Odds ratio (95% CI) P
Age (y) > 70 1.14 (0.64–2.04) 0.654
PS ≥ 1 3.14 (1.63–6.04) 0.001* 1.43 (0.55–3.73) 0.461
GS≥ 9 1.07 (0.58–2.00) 0.827
PSA (ng/ml) > 100 2.55 (1.41–4.58) 0.002* 2.35 (1.07–5.18) 0.034* 2.84 (1.33–6.03) 0.007*
Hb (g/dl) < 12 1.95 (1.03–3.72) 0.042* 2.03 (0.80–5.15) 0.136 2.50 (1.09–5.73) 0.030*
LDH (U/L) > 300 2.03 (1.10–3.74) 0.023* 1.08 (0.45–2.60) 0.864
ALP (U/L) > 350 1.98 (1.07–3.67) 0.030* 1.98 (0.83–4.69) 0.122
Bone meta at diagnosis 1.00 (0.55–1.81) 0.998
Time to CRPC (y) < 1 1.42 (0.79–2.54) 0.238
DTX cycle< 10 1.81 (0.95–3.43) 0.071
ABI or ENZA 1.66 (0.76–3.60) 0.201
Low Initial CBZ dose 2.22 (1.11–4.43) 0.023* 2.15 (0.48–9.76) 0.32 2.81 (1.11–7.13) 0.030*
RDI 60% or lower 2.76 (1.24–6.17) 0.013* 1.26 (0.36–4.34) 0.717
PS performance status, DTX docetaxel, ABI abiraterone, ENZ enzalutamide
RDI:relative dose intensity, *P < 0.05
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has a potential to enhance the RDI, causing longer sur-
vival after treatment. However, our study was retrospect-
ive and the CBZ treatment protocol differed between
institutes and physicians. The results might be influenced
by some selection bias, which suggests that other patient
characteristics were likely to explain the difference in OS.
Moreover, the RDI of CBZ was smaller than 60% in many
patients. In the real world, we had easily decreased the
dose of CBZ because of high rate adverse events such as
neutropenia. Based on the results of this study, we need to
make efforts to increase the RDI so that CBZ can be used
effectively. The appropriate dose of CBZ should be deter-
mined based on the disease status and characteristics in
each patient.
In the PROSELICA study, grade 3 and 4 neutropenia
was observed in 57.1 and 82.1% of patients treated with
20mg/m2 and 25 mg/m2 CBZ, respectively, which sup-
ports the notion that a lower dose of CBZ may decrease
the hematological toxicity rate [7]. In our study, grade 4
neutropenia was significantly less frequently observed in
the low-dose group (36%) than in the high-dose group
(65%; P < 0.001), which is similar to the results of the
PROSELICA study. Moreover, grade 4 neutropenia was
not significantly associated with age or PS in our study,
which supports the possibility that low-dose CBZ could
be safe even for older patients and/or those with low PS.
Kosaka et al. reported that the presence of grade 3 or 4
neutropenia after CBZ treatment was significantly corre-
lated with longer OS [8]. In our study, the presence of
grade 4 neutropenia was correlated with longer OS after
CBZ treatment (data not shown). These results indicated
that the high-dose CBZ induced high-grade neutropenia
associated with longer survival for docetaxel-resistant
prostate cancer patients.
The PSA response rate in our study was 19%, which is
significantly lower than those in the TROPIC and PRO-
SELICA studies. The proportion of patients who re-
ceived abiraterone or enzalutamide was also different
between the studies; i.e., 0, 26, and 79% in TROPIC,
PROSELICA, and our study, respectively. We previously
reported that patients treated sequentially with abirater-
one and enzalutamide showed a poorer response to the
second than to the first treatment [9]. Therefore, one
possible explanation for the lower PSA response rate in
our study is that a much higher proportion of our pa-
tients than the TROPIC or PROSELICA patients had
previously received abiraterone or enzalutamide.
Elucidating an appropriate treatment sequence using
novel hormone treatments including abiraterone and
enzalutamide and taxane chemotherapies including do-
cetaxel and CBZ is important for maximizing clinical
benefit in CRPC patients. We previously identified fac-
tors predicting efficacy in CRPC patients treated with
enzalutamide [10]. We found that Gleason score, time to
CRPC, PS, and previous steroid treatment were signifi-
cantly associated with shorter PFS. In contrast, in the
present study, only existing bone metastasis at diagnosis
associated with PFS. By using these known baseline clin-
ical parameters, we can predict the efficacy of novel
treatments for prostate cancer. However, they are not
perfect for selecting the best treatment sequence.
Achieving precision medicine will require more precise
Table 4 Number of adverse effects of CBZ treatment
Total (n = 118) High (n = 37) Low (n = 81) P (High vs Low)
Grade 4 neutropenia 53 (45%) 24 (65%) 29 (36%) < 0.001*
Febrile neutropenia 30 (25%) 13 (35%) 17 (21%) 0.118
Grade 3 thrombocytopenia 9 (8%) 6 (16%) 3 (4%) 0.026*
Grade 3 nausea 17 (14%) 5 (14%) 12 (15%) 1
Grade 2 diarrhea 13 (11%) 4 (11%) 9 (11%) 1
Grade 2 malaise 19 (16%) 4 (11%) 16 (20%) 0.296
Pneumonia 5 (4%) 2 (5%) 3 (4%) 0.648
*P < 0.05




Odds ratio (95% CI) P Odds ratio (95% CI) P
Age (y) > 70 58 (49%) 1.45 (0.68–3.09) 0.340 1.99 (0.85–4.64) 0.113
PS ≥ 1 62 (53%) 0.55 (0.26–1.18) 0.126 0.71 (0.30–1.66) 0.425
DTX cycle< 10 72 (61%) 0.56 (0.26–1.12) 0.146 0.53 (0.22–1.25) 0.148
PEG GCSF use 97 (82%) 0.73 (0.27–2.02) 0.548 0.94 (0.28–3.18) 0.916
Low initial CBZ dose 81 (69%) 0.21 (0.08–0.52) < 0.001* 0.21 (0.08–0.59) 0.002*
PS performance status, DTX docetaxel, PEG:pegfilgrastim, *P < 0.05
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tissue- or liquid-based biomarkers beyond these clinical
parameters [11].
There are several limitations to our study. The number
of patients is too small to allow precise statistical ana-
lyses. In addition, the study was retrospective and lacked
a control group, and the treatment protocol differed be-
tween institutions. Moreover, we missed some prognos-
tic parameters of the patients, such as metastatic status
at the time of CBZ treatment, the efficacy of previous
docetaxel, abiraterone, and enzalutamide, and the usage
of bone-modifying agents, such as bisphosphonates,
denosumab, and alpharadin. However, to our knowledge,
this is the largest study (118 patients) of the treatment
efficacy and toxicity of CBZ in Japanese patients to date.
Further prospective studies are needed to determine the
optimal dose of CBZ for Japanese subjects with CRPC.
Conclusions
Existing bone metastasis and high PSA levels predicted
shorter PFS and OS, respectively, after CBZ treatment.
CBZ at higher initial doses may have similar response
rate and response duration, but longer survival duration
after treatment with higher toxicity than lower initial
doses for docetaxel-resistant CRPC in Japanese patients.
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